Predicting tuberculosis: Does the IGRA tell the tale?

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 10, 2008, Pages 1055-1057

  Stout, Jason E ^a   Menzies, Dick ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; ISONIAZID; PLACEBO; TUBERCULOSTATIC AGENT;

CROSS REACTION; EDITORIAL; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION; COHORT ANALYSIS; GAMBIA; GERMANY; MYCOBACTERIUM BOVIS; NOTE; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

COHORT STUDIES; CROSS REACTIONS; GAMBIA; GERMANY; HUMANS; INTERFERON TYPE II; MYCOBACTERIUM BOVIS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 43849096431     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200802-251ED     Document Type: Editorial

References (11)

1. Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 2000;4:895-903.
2. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the US Navy: its distribution and decline. Am Rev Respir Dis 1974;110:572-580.
3. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, Klein M, Vaughn A, Besch CL, Perez G, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997;337:315-320.
4. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-1204.
5. Canadian Tuberculosis Committee. Interferon gamma release assays for latent tuberculosis infection: an Advisory Committee Statement (ACS). Can Commun Dis Rep 2007;33:1-18.
6. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Clinical Guideline 33 [Internet] [accessed February 3, 2008]. Available from: http://www.nice.org.uk/nicemedia/pdf/word/ CG033NICEguidelineword.doc
7. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54:49-55.
8. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole-blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-1170.
9. Leyten EM, Arend SM, Prins C, Cobelens FG, Ottenhoff TH, van Dissel JT. Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 2007;14:880-885.
10. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-354.
11. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007;4:e192.